Navigation Links
Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
Date:3/28/2008

- Company Plans to Request Timely Hearing before a NASDAQ Listing

Qualifications Panel -

FREMONT, Calif., March 28 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML, VRMLD) (the "Company"), a molecular diagnostics company, announced today that on March 18, 2008, the Company received communication from The NASDAQ Stock Market ("NASDAQ") that, as a result of the Company's common stock closing at $1.00 per share or more for a minimum of 10 consecutive business days, it has achieved compliance with the minimum bid price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4) ("Rule 4310(c)(4)").

The communication follows a notice of noncompliance from NASDAQ dated September 6, 2007, which was disclosed by the Company on September 7, 2007, that indicated that the Company failed to comply with the minimum bid price requirement for continued listing set forth in Rule 4310(c)(4). The notice of noncompliance gave the Company notice that the bid price of its common stock had closed under $1.00 per share for the previous 30 business days, and stated that if the Company could not demonstrate compliance with Rule 4310(c)(4) by March 4, 2008, the NASDAQ staff would determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 4310(c), except for the bid price requirement.

The bid price requirement was met in part as a result of the 1-for-10 reverse stock split of the Company's outstanding common stock effected by the filing of the Company's Third Amended and Restated Certificate of Incorporation on February 29, 2008, which was disclosed by the Company on March 3, 2008. The reverse stock split was effec
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...v. 6 ,, 3Q09 Corpo...tenza(TM) E.U. Marketing Authorization to Astellas... commercial readiness activities Expanded managem...keting; and Director, Commercial Operations Appoi...Audit Committee chairman , Upcoming 2009 Mi...
(Date:11/6/2009)...he agenda for Arrowhead’s 2010 Personalized ...take place on February 22-24, 2010 in Philadelphia... we will highlight key issues in forming partnersh...periences. , Minneapolis,...owhead’s 2010 Personalized Medicine Partner...
(Date:11/5/2009).... 5 DSM Pharmaceutical Products to...iance with Galenix, Saint Jean D,Illac, France, wh...ufacturing partner for Galenix commercial products...laborate on business development opportunities co-...d on the strength of Galenix in drug product devel...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC B...ults for the quarter ended September 30, 2009. The...tables that follow. ,, Third Quarter 2009 ,...$0.01 per share for the third quarter of 2009 as c...re for the third quarter of 2008. ,, Net sales...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...b3c newswire /  - Rentschler Biotechnologie a... biopharmaceutical development and production, hav...operation will enable Rentschler Biotechnologie&rs...im’s large-scale mammalian biopharmaceutical...ce versa, Boehringer Ingelheim’s clients to ...
...rapeutics (Prime), a,thought leader in pharmacy be...ived accreditation from the National Association o...fied Internet Pharmacy Practice,Sites(TM) (VIPPS(R...tablished by NABP in response to,consumers, concer...he,Internet. VIPPS accreditation further authentic...
...stems, Inc., a,privately held company that manufac...nnounced today the newest installation of the PEM ... P.C. in Rockville Centre, New York.,This installa...een Naviscan,and the operators of Rockville PET Im...ging technology to multiple centers throughout the...
Other Biology Technology:Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 2Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 3Prime Therapeutics Receives VIPPS Accreditation 2Naviscan PET Systems and Rockville PET Imaging Partner to Bring a New Breast Imaging Technology to New York 2Naviscan PET Systems and Rockville PET Imaging Partner to Bring a New Breast Imaging Technology to New York 3
(Date:11/9/2009)...the Netherlands, November 09, 2009 / b3c newswire...ization, and Seventh Wave, an American organizatio...that the companies have signed a letter of intent ...tinal models TIM. The letter of intent proposes a ...o TIM systems for commercialization in North Ameri...
(Date:11/9/2009)...ELPHIA Scientists and industry leaders from aroun..., for the AACR-NCI-EORTC Molecular Targets and Can...ill feature groundbreaking information on importan... a complex disease and to treat it effectively we ...takes place at the molecular level," said Lewis Ca...
(Date:11/8/2009)...T LAFAYETTE, Ind. - Researchers at Purdue Universi...maged nerve fibers in spinal cord injuries using n...shortly after an accident. , The synthetic "copo... nanometers in diameter, or roughly 100 times smal...earchers have been studying how to deliver drugs f...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Depression May Lead to More Preemies Among Blacks 49006 1Depression May Lead to More Preemies Among Blacks 49006 2Good news for some hard to treat hepatitis C patients 49004 1Good news for some hard to treat hepatitis C patients 49004 2Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 1Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 2Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 3
...mmals React to Underwater Sound , Connie Barclay,...ries Service is looking at how marine mammals reac...ts that exposure to intense underwater sound in so...rand and ultimately die. Some of these strandings ...itary sonar, and most have involved beaked whales;...
... newly sequenced genome of a one-celled, planktoni...14) in the journal Nature, is already telling scie...nied the jump from one-celled life forms to multic...aper and a complementary Science paper also releas...biologists Nicole King, Daniel Rokhsar and their c...
...vast and far-reaching as the worlds oceans are, ev...es, according to a study in the journal Science by...t Chapel Hill and others. , The international tea...ects of global change from overfishing to global ...ems, such as coral reefs and continental shelves. ...
Other Biology News:NOAA science story tips -- AAAS 2008 edition 2NOAA science story tips -- AAAS 2008 edition 3NOAA science story tips -- AAAS 2008 edition 4NOAA science story tips -- AAAS 2008 edition 5NOAA science story tips -- AAAS 2008 edition 6NOAA science story tips -- AAAS 2008 edition 7Genome of marine organism tells of humans' unicellular ancestors 2Genome of marine organism tells of humans' unicellular ancestors 3Genome of marine organism tells of humans' unicellular ancestors 4First map of threats to marine ecosystems shows all the world's oceans are affected 2
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
...ct measuring instrument for calibrating single-cha...ompact design and the robust carrying case, the MC... laboratory and on-site at the users premises. The...ual channels are tested automatically. Multi-chann...
...tol DTT White solid.. PACKAGED UNDER INERT GAS. ...action is "driven" to completion. A protective age... found in many other preparations. Blocks the leth... ≥97% by titration. Contaminants: Heavy metal...
Biology Products: